Medtronic delivered a strong fiscal Q2 2026, with revenue reaching $9.0 billion, representing 6.6% reported growth and 5.5% organic growth, which beat expectations by 75 basis points. Adjusted EPS increased 8% year-over-year to $1.36, driven by robust performance in Cardiovascular (+9%) and accelerating contributions from its Pulse Field Ablation (PFA) franchise, which grew 71%. Management raised full-year fiscal 2026 guidance, projecting organic revenue growth of approximately 5.5% and EPS between $5.62 and $5.66, citing significant momentum in new product launches like the Simplicity hypertension treatment and Altaviva for incontinence. Despite deliberate increases in R&D and SG&A spending to fuel this growth, operating margins remained resilient, and the company signaled a shift to an aggressive 'growth mindset' with high single-digit EPS growth expected to continue into fiscal 2027.
| Metric | Value | Change |
|---|---|---|
| Q2 Revenue | $9.0 Billion | +6.6% Reported / +5.5% Organic |
| Q2 EPS | $1.36 | +8% |
| Cardiovascular Portfolio Growth | 9% | Strongest in a decade |
| PFA Growth | 71% | Acceleration from Q1 |
| Adjusted Gross Margin | 65.9% | +70 bps YoY |
| Diabetes Orders (New Sensors) | >35,000 | New metric |
Management emphasized that the Cardiac Ablation (PFA) business is the primary driver of current acceleration, growing 71% with over 300% growth in the US. This is supported by the doubling of the installed base of Affera mapping systems during the quarter, which serves as a leading indicator for future consumables revenue. The company stated this is the 'highest growth rate of any company in this large and fast-growing space' and expects further acceleration in Q3, signaling that Medtronic is successfully taking share in a multi-billion dollar market.
The receipt of the final Medicare NCD for Simplicity (hypertension treatment) was highlighted as a major strategic victory, described as a 'best-case scenario' that removes barriers to access. Management noted that commercial payers are covering 30 million lives and coming online 'faster than anticipated.' With 18 million addressable patients in the US, management views this as a 'massive multi-billion dollar opportunity' where the only variable is the speed of adoption, not the ultimate market size.
A strategic pivot toward reinvestment was evident, as management explicitly chose to increase OpEx in Q2 to support the launch of PFA and Simplicity rather than maximizing short-term margins. R&D increased 8.9% (230 basis points ahead of revenue growth), and SG&A investments were prioritized in sales and marketing. This indicates a capital allocation shift focused on securing long-term revenue streams and market share in high-growth segments like robotics and neuromodulation.
The Diabetes segment is showing signs of a significant inflection point driven by new product launches. Management reported over 35,000 orders for new sensors (Simplera Sync and Instinct), with 25% coming from new patients or pump users not previously using Medtronic CGM. This 'order inflection,' combined with the planned separation of the business by the end of calendar 2026, suggests a strategic focus on unlocking value and stabilizing a segment that has faced recent headwinds.
Gross margin faced headwinds from business mix, specifically the lower margin capital equipment sales in Cardiac Ablation and the early manufacturing ramp of the Simplera diabetes sensor. While operational improvements provided 70 basis points of benefit, negative mix offset this by 80 basis points. Management noted that these mix headwinds will persist into the second half of the year, potentially limiting margin expansion despite revenue growth.
The company faces significant external costs from tariffs, estimated at $185 million for fiscal 2026, with $90-95 million impacting Q3 alone. This creates a volatile earnings profile, as seen in Q2 where a tax benefit helped offset costs, but Q3 margins are expected to be down a couple hundred basis points sequentially due to these tariff impacts.
The Surgical and MedSurg portfolio grew only 1%, lagging behind the company's overall acceleration. Management attributed this to tender timing in emerging markets and pressure from bariatric surgery shifts. While a rebound is expected, the sluggishness in this large portfolio highlights that the turnaround is not yet broad-based across all segments.
Management acknowledged a 40% decline in Cryoablation revenue, which is being cannibalized by the shift to PFA technology. While PFA growth is more than offsetting this loss, the rapid decline of an established revenue stream creates a reliance on the continued hyper-growth of the new PFA franchise to maintain overall portfolio growth.
Overall: Management exhibited a highly confident and assertive demeanor, repeatedly emphasizing that the company has reached an inflection point and 'turned the page' to a period of accelerated growth. The tone shifted from defensive restructuring to offensive market capture, with executives using phrases like 'game changers' and 'incredible trajectory' to describe their new product portfolio. There was a notable lack of hesitation regarding the uptake of new technologies, focusing instead on the speed of execution rather than the feasibility of the products.
Confidence: HIGH - Management provided specific, granular data points to support their optimism, such as the 71% growth in PFA, 300% growth in US PFA, and 35,000 orders for new diabetes sensors. They explicitly raised guidance immediately after beating earnings and made definitive statements about market share gains and the 'runway' for future growth, indicating strong conviction in their projections.
Approximately 5.5% organic (Raised from ~5.0%)
$5.62 to $5.66 (Raised from $5.60 to $5.66)
$1.32 to $1.34
High Single Digits
Hedging & Uncertainty: Management used very limited hedging regarding their core growth drivers, replacing uncertainty language with temporal qualifiers focused on speed. Phrases like 'question of how fast' and 'sprinting after this opportunity' indicate high certainty about the market opportunity. However, standard forward-looking qualifiers were present regarding external factors, such as 'Based on recent rates, we now see an FX tailwind' and 'We expect a tariff impact... of approximately $185 million.' There was slight hedging on the precise timing of the Simplicity ramp, stating they 'have not incorporated much Simplicity revenue into our back half guidance,' which provides a buffer for future beats.
Medtronic is on the cusp of an acceleration in our financial results and our strategy... that acceleration is indeed underway. - Geoffrey Martha, Chairman and CEO
This isn't a question of if or even how big. A question of how fast. - Geoffrey Martha, Chairman and CEO
We're shifting to a growth mindset... We took the opportunity to increase OpEx investments to support our revenue growth momentum. - Geoffrey Martha, Chairman and CEO
We made some significant investments... to make sure we fully capture the opportunities that are ahead of us. - Thierry Pieton, Chief Financial Officer
We remain committed to driving both revenue and earnings growth... Medtronic has turned the page and entered a new period of greater revenue and earnings growth. - Geoffrey Martha, Chairman and CEO
Analyst Sentiment: Analysts were highly engaged and constructive, focusing heavily on the mechanics of the new growth drivers, specifically the ramp speed of Simplicity (hypertension) and the margin profile of the PFA business. Questions indicated a desire to quantify the 'how fast' variable management emphasized.
Management Responses: Management responses were detailed and data-rich, often bringing in specific clinical or commercial nuances (e.g., Dr. Laura Mori on NCD specifics). They displayed patience in explaining the 'algorithm' of their investments and margin expansion, reinforcing their strategic thesis without deflecting on the near-term financial impacts.
Detailed discussion on the Simplicity NCD and commercial payer coverage, with management clarifying that restrictions are minimal and the final NCD is better than the proposal.
Analysis of the 'algorithm' for margin expansion, where management explained that current investments in SG&A and R&D would lead to leverage in the second half and fiscal 2027.
Inquiries into the cannibalization of existing products (Cryo, Sacral Nerve stimulation) by new tech (PFA, Altaviva), with management asserting that new tech is net accretive and expands the market.
Questions regarding M&A strategy, with management confirming a focus on 'tuck-in' acquisitions in higher-growth segments like cardiology and neuroscience.
Medtronic has successfully transitioned from a turnaround story to a growth story, driven by the execution of a robust multi-year product pipeline. The Q2 results validate the strategy, with PFA leading the charge and massive new markets in Hypertension (Simplicity) and Incontinence (Altaviva) opening up. The decision to reinvest profits to secure these growth engines, rather than maximizing immediate margins, is the right strategic move for long-term value creation. With raised guidance, high single-digit EPS growth projected for FY27, and a clear path to $1B+ in incremental revenue from PFA alone, the risk/reward profile is highly attractive. The separation of the Diabetes segment in 2026 further unlocks hidden value.
The final Medicare NCD for Simplicity was broader than anticipated, removing barriers like kidney function exclusions and reducing time requirements. This signals a potentially easier reimbursement pathway for novel medtech procedures going forward.
Management noted ongoing but 'manageable' volume-based procurement (VBP) impacts in China, particularly in Neurovascular, but still managed mid-single-digit growth in the region.
Tariffs remain a specific headwind, estimated at $185 million for the fiscal year, impacting COGS and creating quarterly margin volatility.